Načítá se...
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Edoxaban, an oral direct inhibitor of factor Xa, was recently approved in the United States and Japan for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for treatment of venous thromboembolism (VTE). It is also licensed in Japan for prevention of VTE...
Uloženo v:
| Vydáno v: | J Thromb Thrombolysis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4608015/ https://ncbi.nlm.nih.gov/pubmed/25669624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-015-1185-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|